trending Market Intelligence /marketintelligence/en/news-insights/trending/gntbzcy0xkuqydxihdjcsq2 content esgSubNav
In This List

Imugene closes A$8.1M rights issue

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Imugene closes A$8.1M rights issue

Australia's Imugene Ltd. closed a previously announced fully underwritten 1-for-9.5 rights issue.

Shareholders subscribed for 139,713,059 shares at 2.7 Australian cents each. The cancer drug developer raised about A$3.8 million.

The resulting shortfall of 160,803,118 shares will be allocated to institutional investors.

The company expects to complete the issue of shares and attaching options under the rights issue July 11.

Imugene develops immunotherapies for gastric and breast cancer.